Market Research Store

The Biosimilar Drug Market 2015: Industry Outlook, Challenges, Strategies & Forecasts 2030

Market Research Store Added New Report Titled "The Biosimilar Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to Its Research Store.


Deerfield Beach, FL -- (SBWIRE) -- 08/19/2015 -- The "Biosimilar Drug Market: 2015 - 2030 Industry Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the biosimilar drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future road map, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for biosimilar drugs from 2015 through to 2030. The forecasts are segmented for over 8 drug classes, 2 approval categories, 5 regions and 25 leading countries.

Do Inquiry For Sample Before Purchasing This Report:

Since their commercial inception in the 1980s, biologic drugs have grown into a $200 Billion market, driven by their effectiveness in key therapeutic areas such as oncology, diabetes and rheumatoid arthritis.

Unlike traditional small molecule drugs, biologic drugs are much harder to replicate and have allowed originators to maintain market dominance even after their patents have begun to expire. However, generic drug manufacturers are keen to invest in the area, eyeing long term revenue opportunities.

Many generic manufacturers are aggressively investing to establish the authenticity of their biosimilar products that aim to mimic biologic drugs at a lower price. Non-approved biosimilars already enjoy widespread proliferation in emerging markets, due to limited clinical requirements and the lack of stringent IP regulation.

Having established regulatory pathways for approving biosimilar drugs, developing markets such as the European Union are also beginning to benefit from a robust biosimilar market. Largely driven by regulatory efforts to reduce healthcare costs, SNS Research estimates that approved biosimilars will account for more than $20 Billion in revenue by the end of 2020.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

Do Inquiry For Buying This Report: href="

Key Findings:

The report has the following key findings:

Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

In terms to drug class categorization, we expect monoclonal antibodies to dominate the biosimilar drugs market by the end of 2020, with an estimated market share of 40%.

SNS Research estimates that biosimilars will cut global healthcare spending by up to $150 Billion by the end of 2020, as several innovator biologic drugs come off patent.

Between 2015 and 2020, SNS Research estimates that over $50 Billion of spending for biologic drugs will lose exclusivity.

In a bid to control costs and expand their global reach, most biosimilar drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China, Brazil and Russia. These countries have been used as successful launch-pads for several prominent biosimilar drugs.

Topics Covered:

The report covers the following topics:

Biosimilar drugs ecosystem

Market drivers and barriers

Technology, economics and key trends

Approved and non-approved biosimilars

Analysis of key drug classes and leading biosimilar drugs

Regulatory landscape of biosimilar drugs throughout the globe

Industry roadmap and value chain

Profiles and strategies of 200 leading ecosystem players, including biosimilar and innovator biologic drug manufacturers

Strategic recommendations for ecosystem players

Market analysis and forecasts from 2015 till 2030

Visit Here to Know More Detail About This Press Release:

Key Questions Answered:

The report provides answers to the following key questions:

How big is the biosimilar drugs opportunity?

What trends, challenges and barriers are influencing its growth?

How is the ecosystem evolving by segment and region?

What will the market size be in 2020 and at what rate will it grow?

Which countries and submarkets will see the highest percentage of growth?

How big is the market for biosimilar monoclonal antibodies?

How does regulation impact the adoption of biosimilar drugs?

How cheap are biosimilar drugs in comparison to their reference products?

What is the cost saving potential of biosimilar drugs?

Who are the key market players and what are their strategies?

How will patent expirations of biologic drugs impact the market?

What are the future prospects of approved and non-approved biosimilar drugs?

What strategies should biosimilar and innovator drug manufacturers adopt to remain competitive?